State Street Corp Tyme Technologies, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$0.23 - $0.35 $2,967 - $4,515	12,900 Added 4.57%	295,170 $83,000
Q1 2022 May 16, 2022	SELL	$0.28 - $0.68 $660 - $1,604	-2,360 Reduced 0.83%	282,270 $99,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $110,880 - $154,560	-112,000 Reduced 28.24%	284,630 $293,000
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $837,861 - $1.37 Million	-734,966 Reduced 64.95%	396,630 $500,000
Q1 2021 May 17, 2021	SELL	$1.34 - $3.53 $76,835 - $202,410	-57,340 Reduced 4.82%	1,131,596 $2.01 Million
Q4 2020 Feb 16, 2021	BUY	$0.87 - $1.26 $283,598 - $410,728	325,975 Added 37.77%	1,188,936 $1.45 Million
Q3 2020 Nov 10, 2020	SELL	$0.93 - $1.35 $2,864 - $4,158	-3,080 Reduced 0.36%	862,961 $846,000
Q2 2020 Aug 14, 2020	SELL	$0.97 - $1.7 $530,124 - $929,084	-546,520 Reduced 38.69%	866,041 $1.15 Million
Q1 2020 May 11, 2020	BUY	$0.9 - $1.95 $1.27 Million - $2.75 Million	1,412,561 New	1,412,561 $1.55 Million

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.